Senator Jim Banks asks the FDA and FTC to investigate

Key insights

• On 3 Jun Senator Jim Banks wrote to acting FDA Commissioner Kyle Diamantas, asking the FDA and FTC to investigate HIMS jointly.
• The requested inquiry covers three issues: whether the Super Bowl ad overstated efficacy, Zepbound KwikPen pricing more than 500% above the TrumpRx most-favoured-nation price, and multi-month subscriptions that do not refund unused medication.
• Banks's core argument is that HIMS's pricing and marketing are undermining TrumpRx's goal of lowering drug prices.
• The regulatory narrative keeps escalating: FDA enforcement in February, then a DOJ referral, now public pressure from a senator.
• The real short-term impact is limited. This is a member of Congress applying pressure by letter, not a formal investigation or enforcement action.
• Watch whether the FDA responds formally and whether this turns into an FTC consumer-protection investigation.

Price action

Closed Friday at $26.19 (-6.5%), dragged down mainly by the broad market rather than anything specific to HIMS: payrolls beat expectations, rate-hike expectations rose and the Nasdaq fell 4%.